{'fraction_non_alphanumeric': 0.010804321728691477, 'fraction_numerical': 0.0, 'mean_word_length': 5.836065573770492, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preclinical screening of in vivo interactions between myelopoietic growth factors and antitumour drugs for therapy of myeloid leukaemia patients (review).

The potential clinical applications of myelopoietic growth factors in the treatment of cancer patients are reviewed. The adverse effects of these myelopoietic growth factors in myeloid leukaemia patients are discussed. The combination of antitumour drugs with these myelopoietic growth factors could overcome these problems in several ways. The clinical benefits of such combined treatment are proposed. The in vivo effects of the myelopoietic growth factors in experimental animal models are summarised. The important data from preclinical screening of in vivo interactions between myelopoietic growth factors and antitumour drugs in myeloid leukaemic patients are emphasised.